Corey Carter
Expertise in
4
conditions

Dr. Corey Carter

Hematology
Wrnmmcb
8901 Wisconsin Ave, 
Bethesda, MD 
Expertise in
4
conditions
Wrnmmcb
8901 Wisconsin Ave, 
Bethesda, MD 

Overview

Corey Carter is a Hematologist practicing medicine in Bethesda, Maryland.

Dr. Carter is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, and Nephrectomy.

He is actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in VA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Wrnmmcb
8901 Wisconsin Ave, Bethesda, MD 20889
Other Locations
Walter Reed National Military Medical Center
8901 Wisconsin Ave, Bethesda, MD 20889

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 30, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
Enrollment Status: Completed
Publish Date: November 18, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

81 Total Publications

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.
Journal: European urology
Published: October 03, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology
Referral may be required

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (0.2 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Savage is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Hormone Replacement Therapy (HRT), and Bone Marrow Transplant.

Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology
Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology
Referral may be required

Office

9609 Medical Center Dr Rm 6E452, 
Rockville, MD 
 (8.0 miles away)
240-276-7239
Languages Spoken:
English

Blanche Alter is a Hematologist and an Oncologist practicing medicine in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Aase Syndrome, Dyskeratosis Congenita, Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
22
conditions
Dr. Craig Kessler
Hematology
Expertise in
22
conditions
Dr. Craig Kessler
Hematology
Referral may be required

MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (6.1 miles away)
202-444-2223
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Craig Kessler is a Hematologist practicing medicine in Washington, Washington, D.c.. Dr. Kessler is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy.

Frequently Asked Questions about Dr. Corey Carter

How do I make an appointment with Dr. Corey Carter?

You can book an appointment with Dr. Corey Carter by calling their office at 301-295-4237. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Corey Carter a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Corey Carter is classified as an Advanced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Corey Carter specialize in?

While Dr. Corey Carter is a Hematology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Corey Carter participate in research or clinical trials?

Yes. Dr. Corey Carter has published 81 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Corey Carter's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carter's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile